Hang Lee joined MGH Biostatistics Center in 2001. He is Associate Director of Collaborative Research & Consulting at the Center and Associate Professor of Medicine at Harvard medical School. He also serves as Associate Director of the Harvard Catalyst (Center for Translational and Clinical Science) Biostatistics Program housed at MGH Biostatistics Center, and lead statistician for the MGH Division of Clinical Research (DCR) Biostatistics Unit. Dr. Lee has extensive collaborative research experience with clinical departments and research programs involving cooperative group coordinating center lead statistician role for national multi-center clinical trials and collaboration with study teams and individual investigators on designing clinical studies, and he co-authored a wide range of collaborative research articles.
Dr. Lee earned his PhD in Biometry from University of Southern California. Dr. Lee’s methodological interests are in the robust inference on clustered- and longitudinal outcomes. Before joining the Center, he was Research Fellow in Biostatistics at Harvard School of Public Health; Instructor at Harvard Department of Psychiatry and Harvard Institute of Psychiatric Epidemiology and Psychiatric Genetics at Massachusetts Mental Health Center; and Director of Biostatistics at UCLA Center for Vaccine Research and Assistant Professor at UCLA School of Medicine.
Joseph J. Locascio, Ph.D. has had a research appointment as a Senior Biostatistician for the Alzheimer’s Disease Research Center and Memory/Movement Disorders Units, Department of Neurology at Massachusetts General Hospital (MGH), Boston, since 1992. He is an Assistant Professor of Neurology at Harvard Medical School as well as a Collaborating Statistician in the Neurology Dept. at Brigham and Women’s Hospital. He is a Consulting Statistician for the Harvard Catalyst Bio-Statistical Consulting Group of Harvard Medical School, and a member of the Statistical Advisory Boards for the journals PLOS One (Public Library of Science) and Lancet-Neurology.
Previously, Dr. Locascio had a dual appointment as research statistician in the Department of Brain and Cognitive Sciences at the Massachusetts Institute of Technology (MIT) from 1992 to 2009 where he also taught formal data analysis courses for four years. He has also taught statistics at Northwestern University (1982) and worked as a statistician in psychiatric research at the University of Chicago (1983-1985) and Bellevue Hospital/New York University Medical Center (1989-1991), and was Research Coordinator for the Mental Health Division of the Chicago Dept. of Health (1976-1979). He has over 100 publications in medical and scientific journals, magazines, and books.
Eric Macklin is an Instructor in Investigation at Massachusetts General Hospital and an Instructor in Medicine at Harvard Medical School. His research interests focus on neurodegenerative and neurodevelopmental diseases with an emphasis on clinical trial design.
He is an Executive Committee member of the Parkinson Study Group and an academic advisor for the Critical Path for Parkinson’s Consortium. He was an organizing member and the lead biostatistician for the Airlie House Clinical Trials Guidelines for ALS research. He is a lead biostatistician for the Healey ALS Center Platform trial, for the phase 3 SURE-PD3 trial in Parkinson disease, and for the Autism Treatment Network. In addition to his work in neurology, he has a long and ongoing interest in evaluation of complementary and alternative medicine, serving as PI or statistician for trials of acupuncture, Tai Chi, and mind-body practices.
Dr. Macklin earned a PhD from Duke University and also holds an MS from Stanford University and an MSc from the Harvard T.H. Chan School of Public Health.
Robert Parker is an Associate Investigator in MGH Biostatistics and an Associate Professor of Medicine at Harvard Medical School.
He is an Associate Director of the Biostatistics and Bioinformatics Core of the Harvard Center for AIDS Research, and Director of the Data Coordinating Center for the PRIME-AIR study. In addition, he works on multiple other R01 studies in HIV (both domestic and international) and has recently started working on projects with the Center for Health Outcomes and Interdisciplinary Research (CHOIR) at MGH.
His research interests are in non-standard study design, non-standard data analysis, and the art of statistical consulting. He is a co-author of the textbook “Planning Clinical Research” published by Cambridge University Press.
Dr. Parker earned an ScD in Biostatistics from the Harvard School of Public Health and an MSc in Medical Statistics from the London School of Hygiene and Tropical Medicine.
Dustin J. Rabideau is Associate Director, Biostatistics and Strategic Initiatives for MGH Biostatistics and an Assistant Professor of Medicine at Harvard Medical School. Dr. Rabideau’s biostatistical research focuses on robust analysis methods for cluster randomized trials and innovative methods to account for participant dropout in clinical trials. Dr. Rabideau also has extensive collaborative research experience providing statistical leadership and expertise for various investigators across MGH. His current research partnerships include the Dauten Family Center for Bipolar Treatment Innovation and the Cancer Outcomes Research and Education Program.
Dr. Rabideau earned a PhD in Biostatistics from the Harvard T.H. Chan School of Public Health. He also holds a MS and MA in Biostatistics from Harvard and a BA in Mathematics and French from SUNY Geneseo.
Harrison Reeder (he/him) is an Instructor in Investigation at MGH Biostatistics and an Instructor in Medicine at Harvard Medical School. His biostatistical research focuses on analysis methods and risk prediction tools for complex survival data, especially in the setting of “semi-competing risks.” He collaborates with multiple groups at MGH, including the Center for Addiction Medicine, and the RECOVER Project study of post-acute sequelae of SARS-CoV-2 (PASC), also known as long COVID. His collaborative research also includes work on a variety of topics including perinatal health and cognitive health in older adults.
Dr. Reeder received his BA in Mathematics/Statistics from Carleton College and PhD in Biostatistics from Harvard University.
David Schoenfeld developed the first omnibus goodness of fit test for the proportional hazards regression model, a model that is used extensively in clinical trials which have survival or time to progression as an endpoint.
He also developed widely used graphical techniques for this model. He authored a popular web site for sample size considerations for clinical trials. He has also developed, along with Dianne Finkelstein, a method of combining endpoints in clinical trials which is favored by the Food and Drug Administration, and he has done research in Bayesian methods for evaluating historically controlled trials and small pediatric trials.
Dr. Schoenfeld was the principal investigator of the Clinical Coordinating Center for the Prevention and Early Treatment of Acute Lung Injury Clinical Network and its successor the Prevention and Early Treatment of Acute Lung Injury network, a national group doing clinical trials in Sepsis and Respiratory Failure. He is a leading statistician in Clinical Trials in Amyotrophic Lateral Sclerosis(ALS).
Currently he is available on a per diem basis for short term consultations on the design and analysis of clinical trials.
Steven Skates is an Associate Professor of Medicine at Harvard Medical School and Associate Investigator at Massachusetts General Hospital (MGH) Biostatistics.
His research interests focus on early detection of cancer, and include biomarker discovery and validation, development of early detection algorithms, and design, conduct, and analysis of early detection trials.
Tanayott Thaweethai (he/him) is Associate Director, Biostatistics Research and Engagement for MGH Biostatistics and an Instructor in Medicine at Harvard Medical School. He develops methods for handling missing data when conducting large observational studies using electronic health records. His research collaboration areas at Mass General include diabetes in pregnancy, clinical effectiveness of type 2 diabetes treatment, and several studies related to COVID-19. He is also lead biostatistician at the Data Resource Core for RECOVER, an NIH research initiative that seeks to understand post-acute sequelae of SARS-CoV-2 (PASC), also known as long COVID.
Dr. Thaweethai received his B.S. in Applied Mathematics – Biology from Brown University and Ph.D. in Biostatistics from Harvard University.
